MTOR and diffuse intrinsic pontine glioma: Recurring focal gains in receptor tyrosine kinases (RTKs) and regulatory cell-cycle genes in addition to phospho-mammalian target of rapamycin (mTOR) immunopositivity have been reported in DIPG and may also represent valid therapeutic targets (28, 29).